Business Wire

CA-PATIENT-SAFETY

21.10.2021 14:02:12 CEST | Business Wire | Press release

Share
Patient Safety Movement Foundation Welcomes New Leadership

The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, today announced Michael A.E. Ramsay, MD, FRCA as its new chief executive officer. Following his appointment, Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc will assume Ramsay’s previous role as chairman. Under their leadership, the organization looks forward to continuing to improve patient safety around the globe.

Dr. Ramsay assumes the role from former CEO, David B. Mayer, MD, who played a pivotal part in helping the organization launch the inaugural #UniteForSafeCare event. During his tenure, Mayer also introduced a new commitment model making it easier for hospitals and healthcare organizations to prioritize patient safety and was a driving force behind the call for a Patient Safety Moonshot .

“We are grateful for all of Dr. Mayer’s efforts over the past three years and believe that Dr. Ramsay is the right leader for this next chapter,” stated Ariana Longley, MPH, chief operating officer at the Patient Safety Movement Foundation. “The leadership, expertise, passion and global connections that Dr. Ramsay and Dr. Durkin bring to the organization position us well to achieve our audacious goals.”

“I am honored to be appointed as CEO,” said Dr. Ramsay. “The last year and a half has put a spotlight on the gaps in our healthcare system. I am excited to work in lockstep with the strong leadership and team at PSMF to forge partnerships that actively promote change, develop and disseminate patient safety education material and create public demand for safe and highly reliable healthcare.”

Prior to being named CEO, Dr. Ramsay was an early member of PSMF set up by Joe Kiani in 2012 and most recently served as chairman of PSMF since 2020. He brings extensive experience serving as chairman emeritus of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas. He is also a professor at the Texas A&M Health Science Center and holds a clinical professorship in anesthesiology at the University of Texas Southwestern Medical School. Ramsay was president of the Baylor Scott and White Research Institute from 2000 to 2020, where the focus was on developing cancer vaccines and early cancer biomarkers. He is past director of anesthesia for the liver transplant program at Baylor and has personally provided anesthesia for over 1,000 liver transplant recipients. He has also held roles in numerous groups, including a current member of the Baylor University Medical Center board of trustees, past president of the International Liver Transplantation Society, committee member of the United Network for Organ Sharing and a member of the American Society of Anesthesiologists committee on transplant anesthesia and “Failure to Rescue: Post-operative Respiratory Depression” workgroup of the PSMF. He was born in Dublin, Ireland, went to Brentwood School in the UK and trained in medicine at The Royal London Hospital. Ramsay was recruited by Baylor University Medical Center in Dallas, Texas in 1976.

Dr. Durkin has been a member of PSMF since 2012 and is transitioning from vice chairman to chairman. Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. Passionate about patient safety, he played an integral role in the assembly of the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. Durkin was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019). Outside of PSMF, he has served as the national director of patient safety for England’s NHS, executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities.

“I am honored to continue to work with the Patient Safety Movement Foundation in this role,” states Durkin. “We have made great progress but are now at a time when we must issue a call to urgent and sustained action for all patients and families as well as political and healthcare leaders, nurses, doctors, pharmacists and therapists of every dimension to continue to educate and empower others to help us reach our goal of zero.”

About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye